EUVIMEDEUVIMED entdecken
Crossref

The prognostic role of pan‐immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617

Satı Coskun Yazgan, Emre Yekeduz, Mine Araz, Hatice Bolek, N Ozlem Kucuk, Yuksel Urun iD

The Prostate · 2025

DOI: 10.1002/pros.24804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Satı Coskun Yazgan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Dipeptides, Inflammation. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pan‐immune inflammation value (PIV) is a newly defined biomarker that includes whole cellular components that are indicators of systemic inflammation in complete blood count (CBC), easily accessible and has the potential to reflect both the body's immune response and systemic inflammation status. This study evaluated the pretreatment PIV for its prognostic impact on overall survival (OS) in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617.

Methods

The PIV was based on the earliest CBC obtained within 1 month before treatment initiation. Patients were categorized into low and high PIV groups based on the median pretreatment PIV, and the relationship between OS and PIV groups was assessed by multivariable analysis.

Results

A total of 43 patients with mCRPC treated with ( 177 Lu)‐PSMA‐617 were included. The median OS was longer in the low PIV group (15.1 months [95% confidence interval [CI] 10.6–19.5]) than in the high PIV group (4.2 months [95% CI 1.7–6.6]) ( p < 0.001). In multivariable analysis, high PIV (hazard ratio [HR]: 4.3, 95% CI 1.194–15.93, p = 0.026) and high Eastern Cooperative Oncology Group performance score (HR: 7.05, 95% CI 1.48–33.46, p = 0.014) were associated with shorter OS.

Conclusion

This study showed that pretreatment PIV might be a prognostic factor in patients with mCRPC treated with ( 177 Lu)‐PSMA‐617.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumDipeptidesInflammationHumansMaleAgedPrognosisMiddle AgedHeterocyclic Compounds, 1-RingAged, 80 and overRadioisotopesProstate-Specific AntigenRetrospective Studies

Stichwörter der Autor:innen

Lutetium‐177‐PSMA‐617metastatic castration‐resistant prostate cancerpan‐immune inflammation value

Substanzen

LutetiumDipeptidesHeterocyclic Compounds, 1-RingLutetium-177PSMA-617RadioisotopesProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey.
  • Cancer Research Institute, Ankara University, Ankara, Turkey.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Nuclear Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey.

ORCID-Profile: Yuksel Urun

Zitieren

APA

Yazgan, S. C., Yekeduz, E., Araz, M., Bolek, H., Kucuk, N. O., & Urun, Y. (2025). The prognostic role of pan‐immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617. The Prostate. https://doi.org/10.1002/pros.24804

Vancouver

Yazgan SC, Yekeduz E, Araz M, Bolek H, Kucuk NO, Urun Y. The prognostic role of pan‐immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617. The Prostate. 2025. doi:10.1002/pros.24804

BibTeX
@article{Yazgan2025,
  author = {Yazgan, Satı Coskun and Yekeduz, Emre and Araz, Mine and Bolek, Hatice and Kucuk, N Ozlem and Urun, Yuksel},
  title = {The prognostic role of pan‐immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium‐177 ( 177 Lu)‐PSMA‐617},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24804}
}
Kostenlos starten →